

Beat C Bornhauser

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8565061/publications.pdf>

Version: 2024-02-01

66
papers

4,247
citations

185998

28
h-index

133063

59
g-index

67
all docs

67
docs citations

67
times ranked

8960
citing authors

#	ARTICLE	IF	CITATIONS
1	Clonal dynamics in pediatric B-cell precursor acute lymphoblastic leukemia with very early relapse. <i>Pediatric Blood and Cancer</i> , 2022, 69, e29361.	0.8	9
2	Pediatric T-ALL type-1 and type-2 relapses develop along distinct pathways of clonal evolution. <i>Leukemia</i> , 2022, 36, 1759-1768.	3.3	4
3	<sc>LRH</sc> interacts with the glucocorticoid receptor to regulate glucocorticoid resistance. <i>EMBO Reports</i> , 2022, 23, .	2.0	7
4	Frequency and prognostic impact of ZEB2 H1038 and Q1072 mutations in childhood B-other acute lymphoblastic leukemia. <i>Haematologica</i> , 2021, 106, 886-890.	1.7	9
5	DYRK1A regulates B cell acute lymphoblastic leukemia through phosphorylation of FOXO1 and STAT3. <i>Journal of Clinical Investigation</i> , 2021, 131, .	3.9	47
6	14q32 rearrangements deregulating <i>BCL11B</i> mark a distinct subgroup of T and myeloid immature acute leukemia. <i>Blood</i> , 2021, 138, 773-784.	0.6	19
7	MAPK-ERK is a central pathway in T-cell acute lymphoblastic leukemia that drives steroid resistance. <i>Leukemia</i> , 2021, 35, 3394-3405.	3.3	28
8	A Hopeful Leap Forward by Multicentric Cooperation for Precision-Based Therapy for Very Resistant, Relapsed, or Refractory Childhood Leukemia. <i>Cancer Discovery</i> , 2021, 11, 1322-1323.	7.7	1
9	BTK inhibition sensitizes acute lymphoblastic leukemia to asparaginase by suppressing the amino acid response pathway. <i>Blood</i> , 2021, 138, 2383-2395.	0.6	13
10	Chemoresistance and Drug Profiling in ALL. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2021, 21, S57-S58.	0.2	2
11	Guidelines for the use and interpretation of assays for monitoring autophagy (4th) <i>Tj ETQq1 1 0.784314 rgBT /Overlock 10 Tf 50,342</i>	4.3	1,430
12	High Immunoproteasome Activity and sXBP1 in Pediatric Precursor B-ALL Predicts Sensitivity towards Proteasome Inhibitors. <i>Cells</i> , 2021, 10, 2853.	1.8	2
13	Single-cell analysis of structural variations and complex rearrangements with tri-channel processing. <i>Nature Biotechnology</i> , 2020, 38, 343-354.	9.4	59
14	TNFR2 is required for RIP1-dependent cell death in human leukemia. <i>Blood Advances</i> , 2020, 4, 4823-4833.	2.5	8
15	Chromatin accessibility landscape of pediatric T-cell lymphoblastic leukemia and human T-cell precursors. <i>EMBO Molecular Medicine</i> , 2020, 12, e12104.	3.3	13
16	Rapid Generation of Leukemogenic Chromosomal Translocations in Vivo Using CRISPR/Cas9. <i>HemaSphere</i> , 2020, 4, e456.	1.2	4
17	The hematopoietic stem cell marker VNN2 is associated with chemoresistance in pediatric B-cell precursor ALL. <i>Blood Advances</i> , 2020, 4, 4052-4064.	2.5	5
18	Pharmacological disruption of the Notch transcription factor complex. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2020, 117, 16292-16301.	3.3	64

#	ARTICLE	IF	CITATIONS
19	Repurposing anthelmintic agents to eradicate resistant leukemia. <i>Blood Cancer Journal</i> , 2020, 10, 72.	2.8	3
20	Constitutive Activation of RAS/MAPK Pathway Cooperates with Trisomy 21 and Is Therapeutically Exploitable in Down Syndrome B-cell Leukemia. <i>Clinical Cancer Research</i> , 2020, 26, 3307-3318.	3.2	28
21	The Central Role of MAPK-ERK Signaling in IL7-Dependent and IL7-Independent Steroid Resistance Reveals a Broad Application of MEK-Inhibitors Compared to JAK1/2-Inhibition in T-ALL. <i>Blood</i> , 2020, 136, 20-20.	0.6	1
22	<i>In Vitro</i> Drug Response Profiling in BCP- and T-ALL Primary Samples Adds a Robust Functional Layer Enabling Optimized Guidance of Individualized Therapy in Relapsed and Refractory Pediatric Acute Leukemia Patients. <i>Blood</i> , 2020, 136, 15-16.	0.6	0
23	Pre-clinical evaluation of second generation PIM inhibitors for the treatment of T-cell acute lymphoblastic leukemia and lymphoma. <i>Haematologica</i> , 2019, 104, e17-e20.	1.7	18
24	Efficient apoptosis requires feedback amplification of upstream apoptotic signals by effector caspase-3 or -7. <i>Science Advances</i> , 2019, 5, eaau9433.	4.7	172
25	Prediction of venetoclax activity in precursor B-ALL by functional assessment of apoptosis signaling. <i>Cell Death and Disease</i> , 2019, 10, 571.	2.7	29
26	The Leukemogenic TCF3-HLF Complex Rewires Enhancers Driving Cellular Identity and Self-Renewal Conferring EP300 Vulnerability. <i>Cancer Cell</i> , 2019, 36, 630-644.e9.	7.7	35
27	β -Catenin-Dependent Signals Maintain BCR-ABL1+ B Cell Acute Lymphoblastic Leukemia. <i>Cancer Cell</i> , 2019, 35, 649-663.e10.	7.7	20
28	Exploiting Necroptosis for Therapy of Acute Lymphoblastic Leukemia. <i>Frontiers in Cell and Developmental Biology</i> , 2019, 7, 40.	1.8	10
29	Pediatric ALL relapses after allo-SCT show high individuality, clonal dynamics, selective pressure, and druggable targets. <i>Blood Advances</i> , 2019, 3, 3143-3156.	2.5	4
30	USP7 Cooperates with NOTCH1 to Drive the Oncogenic Transcriptional Program in T-Cell Leukemia. <i>Clinical Cancer Research</i> , 2019, 25, 222-239.	3.2	66
31	Inducible Phase Separation of GSK3 β As a Mechanism for Asparaginase Resistance in Acute Leukemias. <i>Blood</i> , 2019, 134, 169-169.	0.6	0
32	<i>IKZF1</i> ⁺ Defines a New Minimal Residual Disease-Dependent Very-Poor Prognostic Profile in Pediatric B-Cell Precursor Acute Lymphoblastic Leukemia. <i>Journal of Clinical Oncology</i> , 2018, 36, 1240-1249.	0.8	194
33	<i>PDX</i> models recapitulate the genetic and epigenetic landscape of pediatric T-cell leukemia. <i>EMBO Molecular Medicine</i> , 2018, 10, .	3.3	38
34	Cooperative Enhancer Activation by TLX1 and STAT5 Drives Development of NUP214-ABL1/TLX1-Positive T Cell Acute Lymphoblastic Leukemia. <i>Cancer Cell</i> , 2018, 34, 271-285.e7.	7.7	48
35	Pediatric T-ALLs Developing into a Type 2 Relapse Originate from Cells That Carry the Potential of Variable Maturation into Subclones with Distinct Chromatin Landscapes. <i>Blood</i> , 2018, 132, 1545-1545.	0.6	0
36	Ex vivo drug response profiling detects recurrent sensitivity patterns in drug-resistant acute lymphoblastic leukemia. <i>Blood</i> , 2017, 129, e26-e37.	0.6	195

#	ARTICLE	IF	CITATIONS
37	CD70 reverse signaling enhances NK cell function and immunosurveillance in CD27-expressing B-cell malignancies. <i>Blood</i> , 2017, 130, 297-309.	0.6	37
38	Clinical or ATPase domain mutations in ABCD4 disrupt the interaction between the vitamin B12-trafficking proteins ABCD4 and LMBD1. <i>Journal of Biological Chemistry</i> , 2017, 292, 11980-11991.	1.6	36
39	Efficient Generation of Multi-gene Knockout Cell Lines and Patient-derived Xenografts Using Multi-colored Lenti-CRISPR-Cas9. <i>Bio-protocol</i> , 2017, 7, e2222.	0.2	2
40	Activation of concurrent apoptosis and necroptosis by SMAC mimetics for the treatment of refractory and relapsed ALL. <i>Science Translational Medicine</i> , 2016, 8, 339ra70.	5.8	92
41	Genomics and drug profiling of fatal TCF3-HLF ⁺ positive acute lymphoblastic leukemia identifies recurrent mutation patterns and therapeutic options. <i>Nature Genetics</i> , 2015, 47, 1020-1029.	9.4	190
42	Drug Response Profiling to Identify Selective Pharmacological Activity in Drug Resistant ALL. <i>Blood</i> , 2015, 126, 2532-2532.	0.6	0
43	Activation of Simultaneous Apoptosis and Necroptosis to Eradicate Drug Resistant Leukemia. <i>Blood</i> , 2015, 126, 1283-1283.	0.6	0
44	Image-based RNA interference screening reveals an individual dependence of acute lymphoblastic leukemia on stromal cysteine support. <i>Oncotarget</i> , 2014, 5, 11501-11512.	0.8	37
45	Cell and Molecular Determinants of <i>In Vivo</i> Efficacy of the BH3 Mimetic ABT-263 against Pediatric Acute Lymphoblastic Leukemia Xenografts. <i>Clinical Cancer Research</i> , 2014, 20, 4520-4531.	3.2	67
46	The activating STAT5B N642H mutation is a common abnormality in pediatric T-cell acute lymphoblastic leukemia and confers a higher risk of relapse. <i>Haematologica</i> , 2014, 99, e188-e192.	1.7	114
47	Leukemia surfaceome analysis reveals new disease-associated features. <i>Blood</i> , 2013, 121, e149-e159.	0.6	63
48	Fibroblast Growth Factor-21 (FGF21) Regulates Low-density Lipoprotein Receptor (LDLR) Levels in Cells via the E3-ubiquitin Ligase Mylip/Idol and the Canopy2 (Cnpy2)/Mylip-interacting Saposin-like Protein (Msap). <i>Journal of Biological Chemistry</i> , 2012, 287, 12602-12611.	1.6	56
49	CD133 Positive Embryonal Rhabdomyosarcoma Stem-Like Cell Population Is Enriched in Rhabdospheres. <i>PLoS ONE</i> , 2011, 6, e19506.	1.1	111
50	Xenografts of highly resistant leukemia recapitulate the clonal composition of the leukemogenic compartment. <i>Blood</i> , 2011, 118, 1854-1864.	0.6	73
51	Alternative technique for intrafemoral injection and bone marrow sampling in mouse transplant models. <i>Leukemia and Lymphoma</i> , 2011, 52, 1806-1808.	0.6	3
52	Tissue Expression and Actin Binding of a Novel N-Terminal Utrophin Isoform. <i>Journal of Biomedicine and Biotechnology</i> , 2011, 2011, 1-18.	3.0	0
53	Have chemosensitizing strategies for multidrug-resistant childhood acute lymphoblastic leukemia come of age?. <i>Expert Review of Hematology</i> , 2010, 3, 369-372.	1.0	2
54	Induction of autophagy-dependent necroptosis is required for childhood acute lymphoblastic leukemia cells to overcome glucocorticoid resistance. <i>Journal of Clinical Investigation</i> , 2010, 120, 1310-1323.	3.9	287

#	ARTICLE	IF	CITATIONS
55	Dexamethasone regulates expression of BRUCE/Apollon and the proliferation of neural progenitor cells. FEBS Letters, 2009, 583, 2213-2217.	1.3	15
56	Myliip makes an Idol turn into regulation of LDL receptor. Cellular and Molecular Life Sciences, 2009, 66, 3399-3402.	2.4	14
57	DOWN'S Syndrome Acute Lymphoblastic LEUKEMIA: A HIGHLY Heterogeneous DISEASE DRIVEN by an Aberrant CRLF2/JAK2 Cooperation â€” A REPORT FROM the lbfm-STUDY GROUP.. Blood, 2009, 114, 11-11.	0.6	2
58	Leukemia-Initiating Cells Are Frequent in Very High Risk Childhood Acute Lymphoblastic Leukemia and Give Rise to Relatively Stable Phenotypes in Immunodeficient Mice.. Blood, 2009, 114, 86-86.	0.6	2
59	Low-dose arsenic trioxide sensitizes glucocorticoid-resistant acute lymphoblastic leukemia cells to dexamethasone via an Akt-dependent pathway. Blood, 2007, 110, 2084-2091.	0.6	53
60	PDGF regulates the actin cytoskeleton through hnRNP-K-mediated activation of the ubiquitin E3-ligase MIR. EMBO Journal, 2006, 25, 1871-1882.	3.5	21
61	Functional activities and cellular localization of the ezrin, radixin, moesin (ERM) and RING zinc finger domains in MIR. FEBS Letters, 2003, 553, 195-199.	1.3	20
62	MSAP Is a Novel MIR-interacting Protein That Enhances Neurite Outgrowth and Increases Myosin Regulatory Light Chain. Journal of Biological Chemistry, 2003, 278, 35412-35420.	1.6	54
63	Identification and characterisation of transcript and protein of a new short N-terminal utrophin isoform. , 2000, 77, 418-431.		20
64	Differential expression of utrophin and dystrophin in CNS neurons: An in situ hybridization and immunohistochemical study. Journal of Comparative Neurology, 2000, 422, 594-611.	0.9	62
65	Neuronal Expression of the ERM-like Protein MIR in Rat Brain and Its Localization to Human Chromosome 6. Biochemical and Biophysical Research Communications, 2000, 279, 879-883.	1.0	18
66	Altered synaptic clustering of GABA receptors in mice lacking dystrophin (mdx mice). European Journal of Neuroscience, 1999, 11, 4457-4462.	1.2	211